New 24-Valent pneumonia vaccine trial aims to protect all ages
NCT ID NCT07600983
First seen May 23, 2026 · Last updated May 23, 2026
Summary
This study tests a new vaccine designed to protect against 24 types of pneumococcal bacteria, which can cause pneumonia and other serious infections. The trial includes 854 participants ranging from 2 months old to older adults, and will check for safety and immune response. The vaccine uses a carrier protein to boost protection, and results will be compared to an existing vaccine.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STREPTOCOCCUS PNEUMONIAE INFECTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.